

Decreased Serum Hepatocyte Growth Factor (HGF) in Individuals with Bipolar Disorder Normalizes after Zinc and Anti-oxidant Therapy

A.J. Russo

Research Director, Health Research Institute/Pfeiffer Treatment Center, Warrenville, Illinois 60555, USA.
Corresponding author email: ajrusso@hriptc.org

Abstract

Aim: To assess serum HGF concentration in individuals with bipolar disorder and investigate the efficacy of zinc therapy on these levels.

Subjects and methods: Serum from 35 individuals diagnosed with bipolar disorder and 19 age and gender similar controls were tested for HGF concentration using ELISAs, and copper and zinc plasma levels using inductively-coupled plasma-mass spectrometry.

Results: HGF serum levels of individuals with bipolar disorder were significantly lower than age and gender similar controls ($P = 0.0021$). HGF serum concentration was significantly lower in Bipolar patients pre-therapy ($P = 0.0009$) and HGF levels normalized post-therapy. Zinc levels in these same individuals also normalized ($P = 0.0046$) and patient's perceived severity of Bipolar symptoms significantly decreased after therapy ($P = 0.0003$). We also found a significant direct correlation between Zinc and HGF serum concentration in the bipolar patients ($P = 0.04$).

Discussion: These results suggest an association between low HGF levels and bipolar disorder and also demonstrate that zinc therapy may be associated with the normalization of HGF levels and decrease in severity of disease.

Keywords: bipolar disorder, hepatocyte growth factor, HGF

Nutrition and Metabolic Insights 2010:3 49–55

doi: 10.4137/NMI.S5528

This article is available from <http://www.la-press.com>.

© the author(s), publisher and licensee Libertas Academica Ltd.

This is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited.



Introduction

Bipolar Disorder is characterized by episodes of mania and depression that are frequently acute, debilitating, and may be associated with gross social dysfunction and an elevated suicide rate.¹⁻⁴

Recent findings indicate that the pathologic process of this disorder is involved in complex interactions between multiple susceptibility genes and environmental factors.^{5,6}

More than two-thirds of people with bipolar disorder have at least one close relative with the disorder or with unipolar major depression, indicating that the disease has a genetic component. The monozygotic concordance rate for the disorder is 40%–70% and dizygotic twins have a 10%–23% concordance rate.^{7,8}

There is also a correlation between DGKH (diacylglycerol kinase eta) and bipolar disorder. DGKH is a key protein in the lithium-sensitive phosphatidyl inositol pathway,⁹ and more recently a link between environmental stress and schizophrenia and possibly bipolar disorder has been revealed.¹⁰

Recent advances in genetics, molecular and cellular biology, molecular neuroscience, and imaging technology have provided a variety of new and sophisticated approaches to evaluate the complex features of this disease. Important among these advances, high density DNA expression microarray technology has recently been widely adapted by scientists in the search for susceptibility genes for bipolar disorder,¹¹⁻¹³ and has helped reveal gene candidates coding for proteins related to mitochondrial function and apoptosis, glutamate receptors, markers of GABAergic neurons, molecular chaperones, and oligodendrocyte proteins are differentially expressed in postmortem brain tissue, peripheral blood cells, and olfactory neuroepithelium between control and bipolar disorder subjects.¹⁴⁻¹⁶

There is also an emerging body of data suggesting that oxidative stress may be associated with the pathophysiology of Bipolar Disorder,¹⁷⁻¹⁹ including increased levels of glutamate found in the brains of patients with mood disorders.²⁰

Hepatocyte growth factor (HGF), an 82 kDa, 674 amino acid residue heterodimeric glycoprotein, was originally isolated from rat platelets.^{21,22} This growth factor has also been called scatter factor,

hepatopoietin A, and mammary growth factor.²³ It is one of a small family of factors lacking significant homology with other known growth factors, but including an HGF-like factor known as macrophage stimulating protein (MSP).²⁴⁻²⁷ HGF has mitogenic, morphogenic, and motogenic effects on hepatocytes, as well as endothelial, mesenchymal and hematopoietic cell types,^{26,28,29} and demonstrates noticeable species cross-reactivity.³⁰

HGF regulates cell growth, cell motility, and morphogenesis by activating a tyrosine kinase signaling cascade after binding to the proto-oncogenic c-Met receptor (translated by the MET gene). HGF is secreted by mesenchymal cells and, although it was first considered to exert biological effects only on specific target cells, it has since been demonstrated to mediate inflammatory responses to tissue injury, and regulate cell growth, cell motility, and morphogenesis in a wide variety of cells. Its ability to stimulate branching morphogenesis, cell migration, survival and proliferation gives it a central role in angiogenesis, tissue regeneration, as well as tumorigenesis.³¹⁻³⁷

Signaling by HGF has also been found to have anti-inflammatory, antifibrotic, and pro-regenerative activity on various types of tissue. But it seems to be particularly active in the nervous system, where it has been found to have neurotrophic and angiogenic activity on CNS neurons, promote both the survival of neurons and the regeneration of injured nerves, and function as a target-derived axonal chemoattractant, guiding axons to their target. As a result, it plays significant roles in the development of the CNS.³⁸

Zinc is well known as one of the most important trace elements in the body. Dietary zinc deficiency is associated with a variety of physiological defects including anorexia, skin lesion, and growth retardation.³⁹ Mechanistic studies demonstrated that zinc deficiency affects a large number of hepatic genes involved in multiple cellular functions. In particular, zinc deficiency has been shown to down-regulate hepatic gene expression of metallothionein (MT), insulin-like growth factor I (IGF-I), insulin-like growth factor binding protein 1 (IGFBP1), cyclin D1, and HGF, which are involved in cell proliferation.⁴⁰⁻⁴²

Genes involved in GABAergic neurotransmission (43.44) and decreased levels of serum GABA⁴⁵ have been associated with Bipolar Disorder. HGF has been



shown to modulate GABAergic activity⁴⁶ and enhance NMDA currents in the hippocampus.⁴⁷

Because of the potential association between HGF, GABA and neurological development and differentiation, and its association with the etiology of neurological diseases, and because zinc deficiency may down regulate HGF synthesis, we tested patients with Bipolar Disease for serum concentration of HGF and then compared those levels with zinc and copper levels as well as perceived severity of disease, before and after zinc therapy.

Materials and Methods

Elisa to measure serum HGF (Elisa Kit, R&D Systems, Minneapolis, Minn.)

All reagents and specimens were equilibrated to room temperature before the assay was performed. A 1:51 dilution of the patient samples was prepared by mixing 10 μ l of the patient's sera with 0.5 ml of Serum Diluent. One hundred microliters of calibrators (20–200 Eu/ml antibodies), positive and negative control serums, serum diluent alone, and diluted patient samples were added to the appropriate microwells of a microculture plate (each well contained affinity purified polyclonal IgG to HGF). Wells were incubated for 60 minutes (± 5 min) at room temperature, then washed 4x with wash buffer. One hundred microliters of pre-diluter anti-human IgG conjugated with HRP was added to all microwells, incubated for 30 minutes (± 5 min) at room temperature, then wash 4x with wash buffer. One hundred microliters of enzyme substrate was added to each microwell. After approximately 30 minutes at room temperature, the reaction was stopped by adding 50 μ l of 1M sulfuric acid, then the wells were read at 405 nm with an ELISA reader (BioRad Laboratories, Inc., Hercules, CA, USA).

Copper and zinc serum concentration

Assay to establish copper and zinc plasma concentration was performed by LabCorp, Inc. (Naperville, IL 60563) using inductively-coupled plasma-mass spectrometry.

Serums

All serums, experimental and control serums were treated in an identical fashion—frozen at -70°C immediately after collection and cell/serum

separation, then stored at -70°C until thawed for use in ELISAs.

Subjects

Experimental and controls

Serum from individuals with diagnosed (psychiatric interview using DSM criteria) Bipolar Disorder ($n = 35$; 18 male; mean age 34 ± 12 years) and controls ($n = 19$; 10 male mean age 41 ± 14 years) was obtained from patients at the Health Research Institute/Pfeiffer Treatment Center. Most of these individuals were previously diagnosed with Bipolar Disorder, then all were assessed using the modified Mood Disorder Questionnaire, before presenting at the Pfeiffer Treatment Center, Warrenville, IL.*

All patients in this study received zinc and B-6 therapy.

Patients ($n = 35$) for this study were chosen randomly as they presented to The Pfeiffer Treatment Center. At the time of the blood draw, six were taking anti-depressants, four were taking anti-epileptic drugs, eight were taking anti-psychotics, eight were taking lithium and nine presented not taking any associated drugs. We did not find any significant difference in HGF serum concentration in any of these groups (ANOVA; $P = 0.995$; $F = 0.157$). All patients presented after having mixed manic and depression episodes.

Patient consent was obtained from all patients involved in this study.

Controls were normal healthy volunteers, all employees of the Pfeiffer Treatment Center.

Severity of disease

A modified questionnaire asking patients to rank the severity of the signs and symptoms of Bipolar Disease, found in the Mood Disorder Questionnaire,⁵⁶ was used to determine the overall severity. Patients were asked to rate on a scale of 0–5 (5 being the highest), behaviors such as; irritability and anger, lack of ability to focus/concentrate, obsessive behavior, trouble sleeping, paranoia, migraines, intrusive thoughts, anxiety, depression and panic. We evaluated the

*The Pfeiffer Treatment Center is a comprehensive treatment and research center, specializing in the care of with neurological disorders, including Bipolar Disorders.



overall severity of Bipolar Disease by establishing the mean of all of the scores for each patient. The overall bipolar behavior assessment includes assessment of all the behaviors (above).

Zinc and anti-oxidant therapy

Individuals in this study who presented to the Pfeiffer Treatment Center with Bipolar Disease were tested for zinc, copper and anti-oxidant levels. Based on deficiencies, they were then prescribed the appropriate dose of anti-oxidants. Pre-therapy patients represent those who were tested when they first presented and were not previously taking any zinc or anti-oxidants. Post-therapy patients received anti-oxidant therapy (One dose—Vitamin C (125 mg), E (50 IU), B6 (37.5 mg) as well as Magnesium (11 mg), and Manganese (3.75 mg) if warranted), and zinc supplementation (as zinc picolinate) (25 mg), for a minimum of 8 weeks. Pre and post therapy patients were different groups.

Statistics

Inferential statistics were derived from unpaired t-test and odds ratios with 95% confidence intervals. ANOVA was used to assess variance between groups.

Results

Serum from 35 individuals diagnosed with bipolar disorder and 19 age and gender similar controls were tested for HGF concentration using ELISAs, and copper and zinc plasma levels were established using inductively-coupled plasma-mass spectrometry (Labcorp, Naperville IL).

HGF serum levels of individuals with bipolar disorder were significantly lower than age and gender similar controls ($P = 0.0018$) (Table 1). HGF serum

Table 1. HGF levels in bipolar disorder patients and controls.

	HGF bipolar	HGF controls
Mean	402.3	573.9
SD	204.5	142.8
SEM	34.6	32.8
N	35	19

Notes: The two-tailed P value equals 0.0021; $t = 3.2457$; $df = 52$; Standard error of difference = 52.859.

concentration before zinc therapy was significantly lower in Bipolar patients when compared to levels post-therapy ($P = 0.0009$) and HGF levels normalized (increased to the level of controls) post-therapy (Table 2). We found a dose dependent correlation between zinc and HGF ($P = 0.04$) (Fig. 1), and zinc levels in these same individuals also rose ($P = 0.0046$) and normalized post-therapy (Table 3) (normal zinc is 90–150 $\mu\text{g}/\text{dL}$). Copper levels decreased post therapy, but not significantly ($P = 0.59$). Patient's perceived severity of overall Bipolar symptoms decreased significantly post therapy ($P = 0.0003$) (Table 4).

Discussion

HGF has been found to be associated with a variety of diseases of the CNS. For instance, immunohistochemistry using anti-HGF antibody has revealed more intense immunolabeling in Alzheimer's disease (AD) than in control brains, and there appears to be a significant correlation between CSF HGF levels and white matter high-signal foci determined on brain magnetic resonance imaging (MRI) in AD patients.⁴⁸ In Amyotrophic lateral sclerosis (ALS), overexpression of hepatocyte growth factor (HGF) in the nervous system attenuates motoneuron death and axonal degeneration and prolongs the life span of transgenic mice overexpressing mutated $\text{Cu}^{2+}/\text{Zn}^{2+}$ superoxide dismutase.⁴⁹ Overexpression of HGF after gene transfer prevented neuronal death in a Parkinson's Disease rat model,⁵⁰ and decreased levels of HGF has been found in autistic children with GI disease.⁵¹

Previous studies have shown a positive correlation between oxidative stress markers and bipolar disorder and have suggested a role of mitochondrial dysfunction in the etiology of the disease.⁵²

Table 2. HGF levels pre and post therapy in bipolar disorder patients.

	HGF pre-therapy	HGF post-therapy
Mean	314.1	534.8
SD	108.4	244.6
SEM	23.7	65.4
N	21	14

Notes: The two-tailed P value equals 0.0009; $t = 3.6511$; $df = 33$; Standard error of difference = 60.449.




Figure 1. Significant dose dependent correlation between zinc and HGF levels ($P = 0.04$).

Mitochondria-related genes may be abnormally expressed in bipolar disorder. Increasing evidence has shown the presence of mitochondrial dysfunctions such as deletion, mutation and abnormal expression of mitochondria-related genes, increased anaerobic glycolysis, and impaired phospholipid metabolism. Because mitochondrial oxidative phosphorylation is the major resource for the generation of reactive oxygen species, mitochondrial dysfunction indicates that oxidative stress may occur in bipolar disorder and that oxidative stress induced damage may be prevented by mood-stabilizing treatment.⁵³

Zinc supplementation has also been found to prevent liver cell injury through attenuation of

Table 3. Zn levels pre and post therapy in bipolar disorder patients.

	Zn pre therapy	Zn post therapy
Mean	74.0	92.4
SD	13.9	21.5
SEM	3.1	5.7
N	20	14

Notes: The two-tailed P value equals 0.0046; $t = 3.0490$; $df = 32$; Standard error of difference = 6.044.

Table 4. Overall severity of bipolar symptoms pre and post therapy.

	Overall severity pre-therapy	Overall severity post-therapy
Mean	3.64	2.54
SD	0.74	0.61
SEM	0.17	0.18
N	19	11

Notes: The two-tailed P value equals 0.0003; $t = 4.1391$; $df = 28$; Standard error of difference = 0.265.

oxidative stress,⁵⁴ and there is evidence suggesting that alcohol-induced liver damage initiates hepatocyte proliferation, and zinc supplementation accelerates liver regeneration, through up-regulating cell proliferation-related proteins such as HGF.⁵⁵

Our results demonstrate that HGF is significantly lower in Bipolar patients compared to controls and we suggest a potential role for HGF deficiency in the etiology of Bipolar Disease by modulating NMDA and GABAergic activity.

The present data, which demonstrates a dose dependent relationship between zinc and HGF, raise the intriguing possibility that HGF levels are raised by zinc therapy and that these higher levels may be associated with improved symptoms, also suggesting that HGF may be playing a role in the etiology of the disease.

Acknowledgements

The author thanks Scott Filer, Executive Director and the entire staff of The Health Research Institute/Pfeiffer Treatment Center, for their support of this research.

The author also thanks Laurie Myers and Kyle Andrews for their technical assistance.

Disclosure

This manuscript has been read and approved by the author. This paper is unique and is not under consideration by any other publication and has not been published elsewhere. The author and peer reviewers of this paper report no conflicts of interest. The author confirms that they have permission to reproduce any copyrighted material.



References

1. Tondo L, Isacson G, Baldessarini R. Suicidal behaviour in bipolar disorder: risk and prevention. *CNS Drugs*. 2003;17:491–511.
2. Manji HK, Lenox RH. The nature of bipolar disorder. *J Clin Psychiatry*. 2000;61 Suppl 13:42–57.
3. Angst F, Stassen HH, Clayton PJ, et al. Mortality of patients with mood disorders: follow-up over 34–38 years. *J Affect Disord*. 2002;68:167–81.
4. Moller HJ, Curtis VA. The bipolar spectrum: diagnostic and pharmacologic considerations. *Expert Rev Neurother*. 2004;6 Suppl 2:S3–8.
5. Carter CJ. Multiple genes and factors associated with bipolar disorder converge on growth factor and stress activated kinase pathways controlling translation initiation: implications for oligodendrocyte viability. *Neurochem Int*. 2007;50:461–90.
6. Sanders AR, Duan J, Gejman PV. Complexities in psychiatric genetics. *Int Rev Psychiatry*. 2004;16:284–93.
7. Kieseppä T, et al. High concordance of bipolar I disorder in a nationwide sample of twins. *Am J Psychiatry*. 2004 Oct;161(10):1814–21.
8. Cardno AG, et al. Heritability estimates for psychotic disorders: the Maudsley twin psychosis series. *Arch Gen Psychiatry*. 1999 Feb;56(2):162–8.
9. Baum AE, et al. A genome-wide association study implicates diacylglycerol kinase eta (DGKH) and several other genes in the etiology of bipolar disorder. *Molecular Psychiatry*. 2008;13:197–207.
10. Carroll LS, Owen MJ. Genetic overlap between autism, schizophrenia and bipolar disorder. *Genome Medicine*. 2009;1:102.
11. Sun X, Wang JF, Tseng M, et al. Down regulation in components of mitochondrial electron transport chain in post-mortem frontal cortex from subjects with bipolar disorder. *J Psychiatry Neurosci*. 2006;31:189–96.
12. Konradi C, Eaton M, MacDonald ML, et al. Molecular evidence for mitochondrial dysfunction in bipolar disorder. *Arch Gen Psychiatry*. 2004;61:300–8.
13. Iwamoto K, Bundo M, Kato T. Altered expression of mitochondria-related genes in postmortem brains of patients with bipolar disorder or schizophrenia, as revealed by large-scale DNA microarray analysis. *Hum Mol Genet*. 2005;14:241–53.
14. Nguyen DV, Arpat AB, Wang N, et al. DNA microarray experiments: biological and technological aspects. *Biometrics*. 2002;58:701–17.
15. Draghici S, Khatri P, Eklund AC, et al. Reliability and reproducibility issues in DNA microarray measurements. *Trends Genet*. 2006;22:101–9.
16. Konradi C. Gene expression microarray studies in polygenic psychiatric disorders: applications and data analysis. *Brain Res Rev*. 2005;50:142–55.
17. Andreazza A, et al. Oxidative stress markers in bipolar disorder: a meta-analysis. *J of Affective Disorders*. 2008;2:135–44.
18. Gama C. Markers of oxidative stress in bipolar disorder and in schizophrenia. *European Psychiatry*. 2009;24:S159.
19. Frey, et al. Increased oxidative stress and DNA damage in bipolar disorder: a twin-case report. *Prog Neuropsychopharmacol Biol Psychiatry*. 2007;31(1):283–5.
20. Hashimoto K, Sawa A, Iyo M. Increased levels of glutamate in brains from patients with mood disorders. *Biol Psychiatry*. 2007;62:1310–16.
21. Nakamura T, et al. Purification and characterization of a growth factor from rat platelets for mature parenchymal hepatocytes in primary cultures. *Proc Natl Acad Sci U S A*. 1986;83:6489.
22. Nakamura T, et al. Partial purification and characterization in hepatocyte growth factor from serum of hepatectomized rats. *Biochem Biophys Res Commun*. 1984;122:450.
23. Sasaki M, et al. Identification of mouse mammary fibroblast-derived mammary growth factor as hepatocyte growth factor. *Biochem Biophys Res Commun*. 1994;199:772.
24. Michalopoulos G, et al. Control of hepatocyte replication by two serum factors. *Cancer Res*. 1984;44:4414.
25. Thaler FJ, Michalopoulos G. Hepatopoietin A: partial characterization and trypsin activation of a hepatocyte growth factor. *Cancer Res*. 1985;45:2545.
26. Zarnegar R, Michalopoulos GK. The many faces of hepatocyte growth factor: from hepatopoiesis to hematopoiesis. *J Cell Biol*. 1995;129:1177.
27. Weidner KM et al. Evidence for the identity of human scatter factor and human hepatocyte growth factor. *Proc Natl Acad Sci U S A*. 1991;88:7001–5.
28. Comoglio PM, Graziani A. (1994) In *Guidebook to Cytokines and their Receptors*, Nicola NA, editor, Oxford University Press, p. 182.
29. Comoglio PM, Graziani A (1994) In *Guidebook to Cytokines and their Receptors*, Nicola NA, editor, Oxford University Press, p. 185.
30. Grant DS, et al. Scatter factor induces blood vessel formation in vivo. *Proc Natl Acad Sci U S A*. 1993;90:1937–41.
31. Nakamura T, et al. Purification and characterization of a growth factor from rat platelets for mature parenchymal hepatocytes in primary cultures. *Proc Natl Acad Sci U S A*. 1986;83:6489.
32. Nakamura T, et al. Partial purification and characterization in hepatocyte growth factor from serum of hepatectomized rats. *Biochem Biophys Res Commun*. 1994;122:1450.
33. Sasaki M, et al. Identification of mouse mammary fibroblast-derived mammary growth factor as hepatocyte growth factor. *Biochem Biophys Res Commun*. 1994;199:772.
34. Michalopoulos G, et al. Control of hepatocyte replication by two serum factors. *Cancer Res*. 1994;44:4414.
35. Warn R, et al. HGF/SF induces mesothelial cell migration and proliferation by autocrine and paracrine pathways. *Exp Cell Res*. 2001 Jul 15;267(2):258–266.
36. Masakazu Y, et al. Hepatocyte Growth Factor (HGF) Produced By Peritoneal Fibroblasts May Affect Mesothelial Cell Morphology And Promote Peritoneal Dissemination. *Int. J. Cancer*. 1996;47:289–293.
37. Weidner KM, et al. Evidence for the identity of human scatter factor and human hepatocyte growth factor. *Proc Natl Acad Sci U S A*. 1991;88:7001–5.
38. Hamanoue M, et al. Neurotrophic effect of hepatocyte growth factor on central nervous system neurons in vitro. *J Neurosci Res*. 1996;43(5):554–64.
39. McClain CJ, Adams L, Sheldlofsky S. Zinc and the gastrointestinal system. *Essential and Toxic Trace Elements in Human Health and Disease*. Edited by AS Prasad. New York: Alan R; Liss Inc, 1988, pp. 55–73.
40. McNall AD, Etherton TD, Fosmire GJ. The impaired growth induced by zinc deficiency in rats is associated with decreased expression of the hepatic insulin-like growth factor I and growth hormone receptor genes. *J Nutr*. 1995;125:874–9.
41. Pfaffl MW, Gerstmayer B, Bosio A, Windisch W. Effect of zinc deficiency on the mRNA expression pattern in liver and jejunum of adult rats: monitoring gene expression using cDNA microarrays combined with real-time RT-PCR. *J Nutr Biochem*. 2003;14:691–702, 2002;283:C623–30.
42. Dieck HT, Döring F, Roth HP, Daniel H. Changes in rat hepatic gene expression in response to zinc deficiency as assessed by DNA arrays. *J Nutr*. 2003;133:1004–10.
43. Oruc L, et al. Association study between bipolar disorder and candidate genes involved in dopaminergic serotonin metabolism and GABAergic neurotransmission: a preliminary report. *Psychiatric Genetics*. 1996;6:213–7.
44. Kelsoe JR, et al. Possible locus for bipolar disorder near the dopamine transporter on chromosome 5. *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics*. 1998;67:533–40.
45. Petty F, et al. Low plasma GABA is a trait-like marker for bipolar illness. *Neuropsychopharmacology*. 1993;9(2):125–32.
46. Bae MH, et al. Hepatocyte growth factor (HGF) modulates GABAergic inhibition and seizure susceptibility. *Experimental Neurology*. 2010;221:129–35.
47. Akimoto M, et al. Hepatocyte growth factor as an enhancer of nmda currents and synaptic plasticity in the hippocampus. *Neuroscience*. 2004;128:155–62.
48. Tsuboi Y, et al. Increased hepatocyte growth factor level in cerebrospinal fluid in Alzheimer's disease. *Acta neurologica scandinavica*. 2003;107:81–6.
49. Sun W, et al. Overexpression of HGF retards disease progression and prolongs life span in a transgenic mouse model of ALS. *The Journal of Neuroscience*. 2002;22(15):6537–48.
50. Koike H, et al. Prevention of onset of Parkinson's disease by in vivo gene transfer of human hepatocyte growth factor in rodent model: a model of gene therapy for Parkinson's disease. *Gene Therapy*. 2006;13:1639–44.



51. Russo AJ, et al. Decreased serum hepatocyte growth factor (HGF) in autistic children with severe gastrointestinal disease. *Biomarker Insights*. 2009;2: 181–90.
52. Andreazza A. Mitochondrial dysfunction and oxidative stress in bipolar disorder. *European Psychiatry*. 2009;24:S15.
53. Wang J-F. Defects of mitochondrial electron transport chain in bipolar disorder: implications for mood-stabilizing treatment. *Can J Psychiatry*. 2007;52(12):753–62.
54. Zhou Z, Wang L, Song Z, Saari JT, McClain CJ, Kang YJ. Zinc supplementation prevents alcoholic liver injury in mice through attenuation of oxidative stress. *Am J Pathol*. 2005;166:1681–90.
55. Kang X, et al. Zinc supplementation enhances hepatic regeneration by preserving hepatocyte nuclear factor-4 (alpha) in mice subjected to long-term ethanol administration. *The American Journal of Pathology*. 2008;172:916D25
56. Hirschfeld RMA. The mood disorder questionnaire: a simple, patient-rated screening instrument for bipolar disorder. *Journal of Clinical Psychiatry*. 2002;4:9–11.

Publish with Libertas Academica and every scientist working in your field can read your article

“I would like to say that this is the most author-friendly editing process I have experienced in over 150 publications. Thank you most sincerely.”

“The communication between your staff and me has been terrific. Whenever progress is made with the manuscript, I receive notice. Quite honestly, I’ve never had such complete communication with a journal.”

“LA is different, and hopefully represents a kind of scientific publication machinery that removes the hurdles from free flow of scientific thought.”

Your paper will be:

- Available to your entire community free of charge
- Fairly and quickly peer reviewed
- Yours! You retain copyright

<http://www.la-press.com>